Zai Lab
Biotechnology ResearchShanghai, China501-1000 Employees
Zai Lab is a mid-sized biopharmaceutical company with operations in China and the United States, anchored by a presence in Shanghai. It conducts biotechnology research and focuses on discovering, developing, and commercializing therapies for conditions with significant unmet patient needs across oncology, autoimmune disorders, infectious diseases and neurological disorders. The firm aims to broaden patient access and health impact, targeting to reach one million patients by 2030, and operates at a commercial stage with activities spanning global markets. In recent developments, it has engaged in collaboration with Boehringer Ingelheim to evaluate a combination therapy that pairs Boehringer Ingelheim's DLL3/CD3 T-cell engager with Zai Lab's antibody-drug conjugate in a Phase Ib/II study, reflecting an emphasis on combination approaches. The organization is described as having a cross-border footprint, with headquarters in Shanghai and operations in the United States, and it is characterized as a mid-sized biotechnology company.
1-888-653-2347 
support@leadiq.com 
